JP2018512403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512403A5 JP2018512403A5 JP2017548211A JP2017548211A JP2018512403A5 JP 2018512403 A5 JP2018512403 A5 JP 2018512403A5 JP 2017548211 A JP2017548211 A JP 2017548211A JP 2017548211 A JP2017548211 A JP 2017548211A JP 2018512403 A5 JP2018512403 A5 JP 2018512403A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydroimidazo
- methoxy
- quinazolin
- morpholin
- ylpropoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130547P | 2015-03-09 | 2015-03-09 | |
| US62/130,547 | 2015-03-09 | ||
| PCT/EP2016/054728 WO2016142313A1 (en) | 2015-03-09 | 2016-03-07 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018512403A JP2018512403A (ja) | 2018-05-17 |
| JP2018512403A5 true JP2018512403A5 (enExample) | 2019-04-18 |
Family
ID=55484986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548211A Withdrawn JP2018512403A (ja) | 2015-03-09 | 2016-03-07 | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20180042929A1 (enExample) |
| EP (1) | EP3268005A1 (enExample) |
| JP (1) | JP2018512403A (enExample) |
| KR (1) | KR20180013850A (enExample) |
| CN (1) | CN107683138A (enExample) |
| AU (1) | AU2016231260A1 (enExample) |
| BR (1) | BR112017019190A2 (enExample) |
| CA (1) | CA2978807A1 (enExample) |
| CL (1) | CL2017002284A1 (enExample) |
| EA (1) | EA201791975A1 (enExample) |
| HK (1) | HK1250645A1 (enExample) |
| IL (1) | IL254168A0 (enExample) |
| MA (1) | MA43840A (enExample) |
| MX (1) | MX2017011607A (enExample) |
| PH (1) | PH12017501644A1 (enExample) |
| SG (1) | SG11201707239WA (enExample) |
| TN (1) | TN2017000385A1 (enExample) |
| WO (1) | WO2016142313A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| EA031493B9 (ru) | 2013-04-08 | 2019-12-18 | Байер Фарма Акциенгезельшафт | Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл) |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| MX2017011635A (es) | 2015-03-09 | 2018-02-09 | Bayer Pharma AG | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida. |
| EP3426657B1 (en) | 2016-03-08 | 2022-07-13 | Bayer Pharma Aktiengesellschaft | 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CA3068324A1 (en) * | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| CN111500587A (zh) * | 2020-04-15 | 2020-08-07 | 湖南省科域生物医药科技有限公司 | Pgr作为治疗子宫内膜异位症的产品中的用途及其检测pgr的试剂盒 |
| EP4143569A4 (en) * | 2020-05-01 | 2024-05-29 | Mayo Foundation for Medical Education and Research | Methods and materials for treating endometrial cancer |
| WO2022140467A1 (en) * | 2020-12-21 | 2022-06-30 | Samson Pharma, Llc | Topical compositions and methods of treating skin diseases and conditions with such compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006287765B2 (en) * | 2005-09-07 | 2011-12-08 | Merck Serono Sa | P13K inhibitors for the treatment of endometriosis |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| CA2796253A1 (en) * | 2010-04-16 | 2011-10-20 | Bayer Intellectual Property Gmbh | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| EP3003377A1 (en) * | 2013-05-31 | 2016-04-13 | Novartis AG | Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer |
-
2016
- 2016-03-07 CN CN201680022080.8A patent/CN107683138A/zh active Pending
- 2016-03-07 US US15/557,036 patent/US20180042929A1/en not_active Abandoned
- 2016-03-07 WO PCT/EP2016/054728 patent/WO2016142313A1/en not_active Ceased
- 2016-03-07 JP JP2017548211A patent/JP2018512403A/ja not_active Withdrawn
- 2016-03-07 AU AU2016231260A patent/AU2016231260A1/en not_active Abandoned
- 2016-03-07 KR KR1020177027607A patent/KR20180013850A/ko not_active Withdrawn
- 2016-03-07 SG SG11201707239WA patent/SG11201707239WA/en unknown
- 2016-03-07 MA MA043840A patent/MA43840A/fr unknown
- 2016-03-07 BR BR112017019190A patent/BR112017019190A2/pt not_active Application Discontinuation
- 2016-03-07 TN TNP/2017/000385A patent/TN2017000385A1/en unknown
- 2016-03-07 CA CA2978807A patent/CA2978807A1/en not_active Abandoned
- 2016-03-07 HK HK18110118.6A patent/HK1250645A1/zh unknown
- 2016-03-07 EP EP16708402.9A patent/EP3268005A1/en not_active Withdrawn
- 2016-03-07 MX MX2017011607A patent/MX2017011607A/es unknown
- 2016-03-07 EA EA201791975A patent/EA201791975A1/ru unknown
-
2017
- 2017-08-27 IL IL254168A patent/IL254168A0/en unknown
- 2017-09-08 CL CL2017002284A patent/CL2017002284A1/es unknown
- 2017-09-08 PH PH12017501644A patent/PH12017501644A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512403A5 (enExample) | ||
| AU2019204938B2 (en) | Mdm2 inhibitors and combinations thereof | |
| US8513266B2 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | |
| JP7221699B2 (ja) | Ａｒ＋乳癌の治療方法 | |
| JP6368353B2 (ja) | 置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類のリンパ腫治療への使用 | |
| JP2017501983A5 (enExample) | ||
| JP5662321B2 (ja) | 骨髄腫の治療のための置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンの使用 | |
| KR102006033B1 (ko) | 치환된 2,3-디하이드로이미다조[1,2-c]퀴나졸린의 용도 | |
| TWI592157B (zh) | 治療增生性疾病及其他由ｂｃｒ－ａｂｌ、ｃ－ｋｉｔ、ｄｄｒ１、ｄｄｒ２或ｐｄｇｆ－ｒ激酶活性所調節之病症之方法 | |
| JP2017528487A5 (enExample) | ||
| AU2013263043B2 (en) | Dosage regimen for a PI-3 kinase inhibitor | |
| WO2016193955A1 (en) | Combinations of kinase inhibitors for treating colorectal cancer | |
| JP2018522062A5 (enExample) | ||
| Suryavanshi et al. | MEK inhibitors in oncology: a patent review and update (2016–present) | |
| JP2018516982A5 (ja) | 免疫療法用組み合わせ組成物 | |
| Sadaba et al. | Comparative pharmacology of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia | |
| Robert et al. | An update on the clinical use of CDK4/6 inhibitors in breast Cancer | |
| RU2020135055A (ru) | Тройная фармацевтическая комбинация, включающая дабрафениб, траметиниб и ингибитор erk | |
| Costa et al. | A Compendium of tyrosine-kinase Inhibitors: Powerful and efficient drugs against cancer | |
| CN101222925A (zh) | 嘧啶基氨基苯甲酰胺和mTOR激酶抑制剂的组合产品 | |
| JPWO2023139241A5 (enExample) | ||
| HK1194995B (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
| HK1194995A (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |